Rigel Pharmaceuticals Company Leadership
| RIGL Stock | USD 20.20 0.17 0.83% |
Rigel Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Rigel Pharmaceuticals suggests that most insiders are panicking. Rigel Pharmaceuticals employs about 162 people. The company is managed by 10 executives with a total tenure of roughly 29 years, averaging almost 2.0 years of service per executive, having 16.2 employees per reported executive.
| Raul Rodriguez CEO CEO and President Director and Member of Fin. Committee |
| Esteban Masuda President Senior Vice President - Research |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-02-04 | Raul R Rodriguez | Disposed 4952 @ 20.92 | View |
Monitoring Rigel Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Rigel |
Rigel Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Rigel Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Rigel will maintain a workforce of about 160 employees by April 2025.Rigel Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.1075 % which means that it generated a profit of $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9905) %, meaning that it created substantial loss on money invested by shareholders. Rigel Pharmaceuticals' management efficiency ratios could be used to measure how well Rigel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.13 this year. Return On Capital Employed is expected to rise to 0.25 this year. At this time, Rigel Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Non Currrent Assets Other will most likely fall to about 1.2 M.The value of Common Stock Shares Outstanding is expected to slide to about 16.8 M. The value of Net Loss is expected to slide to about (70.7 M)
Rigel Pharmaceuticals Workforce Comparison
Rigel Pharmaceuticals is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,305. Rigel Pharmaceuticals retains roughly 162 in number of employees claiming about 12% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29. Rigel Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rigel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rigel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Rigel Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 2.0 | 22 | 11 | 456,770 | 152,986 |
| 2024-03-01 | 2.8333 | 17 | 6 | 3,357,250 | 80,041 |
| 2023-03-01 | 2.5 | 10 | 4 | 1,678,000 | 36,506 |
| 2022-12-01 | 4.0 | 4 | 1 | 350,000 | 187,500 |
| 2018-09-01 | 1.3333 | 8 | 6 | 503,500 | 228,500 |
| 2018-06-01 | 14.0 | 14 | 1 | 1,312,500 | 5,000 |
| 2017-12-01 | 0.1176 | 2 | 17 | 180,000 | 370,796 |
| 2017-09-01 | 1.0 | 1 | 1 | 80,000 | 5,000 |
| 2017-03-01 | 7.0 | 7 | 1 | 1,025,000 | 5,000 |
| 2016-12-01 | 0.1333 | 2 | 15 | 450,000 | 573,774 |
| 2015-06-01 | 2.3333 | 7 | 3 | 321,666 | 93,332 |
| 2014-12-01 | 1.0 | 1 | 1 | 1,000.00 | 1,000.00 |
| 2014-03-01 | 6.0 | 6 | 1 | 950,000 | 20,000 |
| 2012-09-01 | 0.3571 | 5 | 14 | 100,002 | 204,155 |
| 2012-06-01 | 1.5 | 6 | 4 | 90,000 | 10,000 |
| 2009-03-01 | 4.0 | 8 | 2 | 868,334 | 53,334 |
| 2007-06-01 | 9.0 | 9 | 1 | 74,222 | 2,222 |
| 2006-06-01 | 1.1667 | 7 | 6 | 70,000 | 174,999 |
| 2005-12-01 | 11.0 | 11 | 1 | 644,994 | 11,604 |
| 2005-06-01 | 4.0 | 8 | 2 | 85,000 | 30,000 |
| 2005-03-01 | 0.9286 | 13 | 14 | 166,417 | 540,981 |
| 2004-12-01 | 0.125 | 2 | 16 | 1,736,110 | 3,948,270 |
| 2004-09-01 | 0.3158 | 18 | 57 | 1,190,844 | 8,268,832 |
| 2004-06-01 | 0.2581 | 32 | 124 | 429,103 | 10,732,792 |
| 2004-03-01 | 0.3448 | 10 | 29 | 591,237 | 2,027,332 |
| 2003-09-01 | 0.9048 | 19 | 21 | 1,459,310 | 187,788 |
| 2003-06-01 | 0.1667 | 1 | 6 | 100.00 | 1,739,001 |
Rigel Pharmaceuticals Notable Stakeholders
A Rigel Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Rigel Pharmaceuticals often face trade-offs trying to please all of them. Rigel Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Rigel Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Raul Rodriguez | CEO and President Director and Member of Fin. Committee | Profile | |
| Esteban Masuda | Senior Vice President - Research | Profile | |
| Joseph Lasaga | Senior Vice President - Business Development and Alliance Management | Profile | |
| Dean CPA | Executive CFO | Profile | |
| Raymond JD | General VP | Profile | |
| Tarek Sallam | Vice Marketing | Profile | |
| David Santos | Executive Officer | Profile | |
| Julie Patel | Senior Resources | Profile | |
| Lisa MD | Executive Officer | Profile | |
| Wolfgang MD | Ex Officer | Profile |
About Rigel Pharmaceuticals Management Performance
The success or failure of an entity such as Rigel Pharmaceuticals often depends on how effective the management is. Rigel Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rigel management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rigel management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.13 | |
| Return On Capital Employed | 0.24 | 0.25 | |
| Return On Assets | 0.11 | 0.11 | |
| Return On Equity | 5.32 | 5.58 |
Rigel Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Rigel Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Rigel Pharmaceuticals within its industry.Rigel Pharmaceuticals Manpower Efficiency
Return on Rigel Pharmaceuticals Manpower
| Revenue Per Employee | 1.1M | |
| Revenue Per Executive | 17.9M | |
| Net Income Per Employee | 107.9K | |
| Net Income Per Executive | 1.7M | |
| Working Capital Per Employee | 443.2K | |
| Working Capital Per Executive | 7.2M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 17.867 | Earnings Share 0.99 | Revenue Per Share | Quarterly Revenue Growth 0.609 | Return On Assets |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.